SCHEMBL1784947

SCHEMBL1784947

CCOC(=O)[C@H](O)COC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.42
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
ALOX15 P16050 3/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
SOAT1 P35610 1/20 0.39
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HIF1A Q16665 1/20 0.36
TRPA1 O75762 1/20 0.36
CYP3A4 P08684 2/20 0.34
TSHR P16473 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
PIN1 Q13526 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1784949 1.00 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL29115603 0.86 ALDH1A1 (0.37) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL29115601 0.86 ALDH1A1 (0.37) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL28956455 0.84 HSD17B10 (0.38) ALDH1A1HSD17B10LMNATSHRTDP1
SCHEMBL3015414 0.82 ALDH1A1 (0.39) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL23335331 0.81 ALOX15 (0.33) ALDH1A1HSD17B10LMNAALOX15CYP1A2
SCHEMBL30231620 0.81 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL29115594 0.81 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL29115592 0.81 ALDH1A1 (0.42) ALDH1A1HSD17B10LMNAALOX15MGAM
SCHEMBL28956430 0.80 ALDH1A1 (0.50) ALDH1A1LMNACYP1A2TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083864-A1 CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING BAYER AG (DE) 2026-03-26 US disclosed
EP-4583926-A1 CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING Bayer Aktiengesellschaft (DE) 2025-07-16 EP disclosed
EP-4308551-B1 NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING BAYER AG (DE) 2025-04-09 EP disclosed
US-12168643-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2024-12-17 US disclosed
WO-2024052550-A1 CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING BAYER AKTIENGESELLSCHAFT (DE) 2024-03-14 WO disclosed
EP-4335462-A1 CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING Bayer AG (DE) 2024-03-13 EP disclosed
EP-4308551-A1 NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING Bayer Aktiengesellschaft (DE) 2024-01-24 EP disclosed
CN-116981658-A Novel contrast agents for magnetic resonance imaging 拜耳股份有限公司 2023-10-31 CN disclosed
US-20220306564-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2022-09-29 US disclosed
WO-2022194777-A1 NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING BAYER AKTIENGESELLSCHAFT (DE) 2022-09-22 WO disclosed
EP-2735561-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors Novartis AG (CH) 2014-05-28 EP disclosed
EP-2501683-B1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS NOVARTIS AG (CH) 2014-04-23 EP disclosed
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-03-27 US disclosed
US-8642635-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-02-04 US disclosed
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-04-18 US disclosed
US-8377978-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-02-19 US disclosed
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-08-09 US disclosed
US-8222286-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-07-17 US disclosed
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2012-05-17 US disclosed
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306564-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS RYR1, SMN1; SMN2, CACNB1 ALDH1A1 818/4885HSD17B10 1532/4885LMNA 2673/4885
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 176/4885HSD17B10 2404/4885LMNA 1888/4885
US-12168643-B2 Compounds for the treatment of neuromuscular disorders RYR1, SMN1; SMN2, CACNB1 ALDH1A1 818/4885HSD17B10 1532/4885LMNA 2673/4885
US-20260083864-A1 CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING CA13, CCR1, GALC ALDH1A1 1811/4885HSD17B10 2510/4885LMNA 914/4885
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 176/4885HSD17B10 2404/4885LMNA 1888/4885
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY REN, SERPINB1, MME ALDH1A1 2474/4885HSD17B10 4424/4885LMNA 589/4885
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 176/4885HSD17B10 2404/4885LMNA 1888/4885
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 175/4885HSD17B10 2394/4885LMNA 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.